Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab Plus Lenalidomide vs R-GemOx in R/R DLBCL
NCT06508658Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Aug 2024
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 28
01
Overview
A Phase 3 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Genmab. Started Aug 2024; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06508658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508658.